benralizumab

Jefferies’ Jeffrey Holford downgraded the rating on AstraZeneca plc (ADR) (NYSE: AZN) from Buy to Hold, while lowering the price target from 4,900p to 4,350p. Limited Catalysts In 2016 Holford believes that there are limited catalysts for the stock in 2016 that could drive multiple...